Hyperhomocysteinemia, hyperfibrinogenemia, and lipoprotein (a) excess in maintenance dialysis patients: A matched case-control study

Atherosclerosis

Volumn 125, Issue 1, 1996, Pages 91-101

  Bostom, Andrew G ^a   Shemin, Douglas ^b   Lapane, Kate L ^c   Sutherland, Patrice ^d   Nadeau, Marie R ^a   Wilson, Peter W F ^d   Yoburn, David ^b   Bausserman, Linda ^e   Tofler, Geoffrey ^f   Jacques, Paul F ^a   Selhub, Jacob ^a   Rosenberg, Irwin H ^a  

^a TUFTS UNIVERSITY   (United States)

^b RHODE ISLAND HOSPITAL   (United States)

^c MEMORIAL HOSPITAL OF RHODE ISLAND   (United States)

^d Framingham Study   (United States)

^e MIRIAM HOSPITAL   (United States)

^f BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Arteriosclerosis; End stage renal disease; Fibrinogen; Homocysteine; Lp(a)

Indexed keywords

CHOLESTEROL; FIBRINOGEN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LIPOPROTEIN A;

ADULT; AGED; AMINO ACID BLOOD LEVEL; AMINOACIDEMIA; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CIGARETTE SMOKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIALYSIS; FEMALE; FIBRINOGEN BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR;

EID: 0030598956     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/0021-9150(96)05865-0     Document Type: Article

References (80)

1. [1] Excerpts From The United States Renal Data System, United States Renal Data System 1995 Annual Report. Am J Kidney Dis 1995;26(Suppl 2):S1.
2. [2] Churchill DN. Comparative morbidity among hemodialysis and continuous ambulatory peritoneal dialysis patients. Kidney Int 1993;43(Suppl 40):S16.
3. [3] Wu G. Cardiovascular deaths among CAPD patients. Peril Dial Bull 1993;4(Suppl):S23.
4. [4] Parfrey PS, Harnett JD. Long term cardiac morbidity and mortality during dialysis therapy. Adv Nephrol 1994;23:311.
5. [5] Stampfer MJ, Malinow MR, Willett WC et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. J Am Med Assoc 1992;268:877.
6. [6] Selhub J, Jacques PF, Bostom AG et al. Association between plasma homocysteine concentrations and extracranial carotid artery stenosis. N Engl J Med 1995;332:286.
7. [7] Arnesen E, Refsum H, Bonaa KH, Ueland PM, Forde OH, Noredrehaug JE. Serum total homocysteine and coronary heart disease. Int J Epidemiol 1995;24:704.
8. [8] Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 1995:346:1395.
9. [9] Wilhelmsen L, Svardsudd K, Korsan-Bengsten K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984;311:501.
10. [10] Stone MC, Thorpe JM. Plasma fibrinogen - a major coronary risk factor. J R Coll Gen Pract 1985;35:565.
11. [11] Meade TW, Mellows S, Brozovic M et al. Haemostatic function and ischaemic heart disease; principle results of the Northwick Park Heart Study. Lancet 1986;2:533.
12. [12] Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease: the Framingham Study. J Am Med Assoc 1987;258:1183.
13. [13] Rosengren A, Wilhelmsen L, Eriksson E, Risberg B, Wedel H. Lipoprotein (a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged men. Br Med J 1990;301:1248.
14. [14] Sigurdsson G, Baldursdottir A, Sigvaldsonason H, Agnarsson U, Thorgeirsson G. Sigfusson N. Predictive value of apolipoproteins in a prospective study of coronary artery disease in men. Am J Cardiol 1992;69:1251.
15. [15] Wald NJ, Law M, Watt HC et al. Apolipoproteins and ischemic heart disease: implications for screening. Lancet 1994;343:75.
16. [16] Schaefer EJ, Lamon-Fava S, Jenner JL et al. Lipoprotein (a) levels and risk of coronary heart disease in men: the Lipid Research Clinics Coronary Primary Prevention Trial. J Am Med Assoc 1994;271:999.
17. [17] Cremer P, Nagel D, Labrot B, Mann H, Muche R, Elster H, Seidel D. Lipoprotein Lp(a) as a predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Gottingen Risk Incidence and Prevalence Study (GRIPS). Eur J Clin Invest 1994;24:444.
18. [18] Bostom AG, Gagnon DR, Cupples LA, Wilson PWF, Jenner JL, Ordovas JM, Schaefer EJ, Castelli WP. A prospective investigation of elevated lipoprotein (a) detected by electrophoresis and cardiovascular disease in women: the Framingham Heart Study. Circulation 1994;90:1688.
19. [19] Harpel PC, Chang VT, Borth W. Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein (a) to fibrin: a potential link between thrombosis, atherogenesis, and sulfhydryl compound metabolism. Proc Natl Acad Sci USA 1992;89:10193.
20. [20] Wilcken DEL, Gupta VJ, Reddy SG. Accumulation of sulphur-containing amino acids including cysteine-homocysteine mixed disulfide in patients on maintenance haemodialysis. Clin Sci 1980;58:427.
21. [21] Kang SS, Wong PWK, Bidani A, Milanez S. Plasma protein-bound homocyst(e)ine in patients requiring chronic hemodialysis. Clin Sci 1983;65:335.
22. [22] Smolin LA, Laidlaw SA, Kopple JD. Altered plasma free and protein-bound sulfur amino acid levels in patients undergoing maintenance hemodialysis. Am J Clin Nutr 1987;45:737.
23. [23] Chauveau P, Chadefaux B. Coude M et al. Hyperhomocyst(e)inemia, a risk factor for atherosclerosis in chronic uremic patients. Kidney Int 1993;43(Suppl 41):S72.
24. [24] Hultberg B, Andersson A, Sterner G. Plasma homocysteine in renal failure. Clin Nephrol 1993;40:230.
25. [25] Kim SS, Hirose S, Tamura H et al. Hyperhomocysteinemia as a possible role for atherosclerosis in CAPD patients. Adv Perit Dial 1994;10:282.
26. [26] Bachmann J, Tepel M, Raidt H et al. Hyperhomocysteinemia and the risk for vascular disease in hemodialysis patients. J Am Soc Nephrol 1995;6:121.
27. [27] Ibels LS, Stewart JH, Mahony JF, Neale FC, Sheil AGR. Occlusive arterial disease in uraemic and haemodialysis patients and renal transplant recipients. Q J Med 1977;146:197.
28. [28] Vaziri ND, Shah GM, Winer RL et al. Coagulation cascade, fibrinolytic system, antithrombin III, protein C and protein S in patients maintained on continuous ambulatory peritoneal dialysis. Thromb Res 1989;53: 173.
29. [29] Cavagna R, Schiavon R, Tessarin C, Papa N, Scorrano D, Casol D, De Silvestro L. Risk factors of ischemic heart disease in patients on continuous ambulatory peritoneal dialysis. 1993;13(Suppl 2):S402.
30. [30] Vaziri ND, Gonzales EC, Wang J, Said S. Blood coagulation, fibrinolytic, and inhibitory proteins in end-stage renal disease: effect of hemodialysis. Am J Kidney Dis 1994;23:828.
31. [31] Parra HJ, Mezdour H, Cachera C, Dracon M, Tacquet A, Fruchart JC. Lp(a) lipoprotein in patients with chronic renal failure treated by hemodialysis. Clin Chem 1987;33:721.
32. [32] Cressman MD, Heyka RJ, Paganini EP, O'Neill J, Skibinski CI, Hoff HF. Lipoprotein (a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation 1992;86:475.
33. [33] Cressman MD, Abood D, O'Neill J, Hoff HF. Lp(a) and premature mortality during chronic hemodialysis treatment. Chem Phys Lipids 1994;67/68:419.
34. [34] Kronenberg F, Konig R, Neyer U et al. Multicenter study of lipoprotein (a) and apolipoprotein (a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 1995;6:110.
35. [35] Gault MH, Longerich LL, Purchase L, Harnett J, Breckenridge C. Comparison of Lp(a) concentrations and some potential effects in hemodialysis, CAPD, transplantation, and control groups, and review of the literature. Nephron 1995;70:155.
36. [36] Black IW, Wilcken DEL. Decreases in apolipoprotein (a) after renal transplantation: implications for lipoprotein metabolism. Clin Chem 1992;38:353.
37. [37] Kario K, Takefumi M, Kobayashi H, Matsuo M, Asada R, Masanobu K. High lipoprotein (a) levels in chronic hemodialysis patients are closely related to the acute phase reaction. Thromb Haemost 1995;74: 1020.
38. [38] Guyton JR, Dahlen GH, Patsch W, Kautz JA, Gotto AM Jr. Relationship of plasma lipoprotein Lp(a) levels to race and to apolipoprotein B. Arterioscler Thromb 1985;5:265.
39. [39] Bostom AG, Shemin D, Lapane KL et al. Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: a case-control study. Atherosclerosis 1995;114:93.
40. [40] McNamara JR, Schaefer EJ. Automated enzymatic standardized lipid analyses for plasma and lipoprotein fractions. Clin Chim Acta 1987;166:1.
41. [41] Warnick GR, Benderson J, Albers JJ. Dextran sulfate-magnesium precipitation procedure for quantitation of high density lipoprotein cholesterol. Clin Chem 1982;28:1379.
42. [42] Clauss A. Gerinnungsphysiologische schnellmethode zur beslimmung des fibrinogens. Acta Haematol 1957;17: 237.
43. [43] Bostom AG, Brosnan JT, Hall B, Nadeau MR, Selhub J. Net uptake of plasma homocysteine by the rat kidney in vivo. Atherosclerosis 1995;116:59.
44. [44] Araki A, Suko Y. Determination of free and total homocysteine in human plasma by high performance liquid chromatography with fluorescence detection. J Chromatogr 1987;422:43.
45. [45] Shin-Buering Y, Rasshofer R, Endres WA. A new enzymatic method for pyridoxal 5′-phosphate determination. J Inherit Metab Dis 1981;4:123.
46. [46] Home DW, Patterson D. Lactobacillus casei assay of folic acid derivatives in 96-well microtiter plates. Clin Chem 1988;34:2357.
47. [47] SAS Version 6.08. SAS Institute Inc., Cary, NC. 1990.
48. [48] Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection. Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). J Am Med Assoc 1993;269:3015.
49. [49] Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. J Am Med Assoc 1995;274:1049.
50. [50] Harker LA, Ross R, Slichter SJ, Scott CR. Homocystine-induced arteriosclerosis. The role of endothelial injury and platelet response in its genesis. J Clin Invest 1976;58:731.
51. [51] Wall RT. Harlan JM, Harker LA. Striker GE. Homocystine-induced endothelial injury in vitro: a model for the study of vascular injury. Thromb Res 1980;18:113.
52. [52] Heinecke JW. Rosen H, Suzuki LA, Chait A. The role of sulfur-containing amino acids in superoxide production and modification of low density lipoprotein by arterial smooth muscle cells. J Biol Chem 1987;262: 10098-10103.
53. [53] Di Minno G. Davi G. Margaglione M et al. Abnormally high thromboxane biosynthesis in homozygous homocystinuria. Evidence for platelet involvement and probucol-sensitive mechanism. J Clin Invest 1993;92: 1400.
54. [54] Lentz SR, Sadler JE. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest 1991;88:1906.
55. [55] Tsai JC. Perrella MA. Yoshizumi M et al. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci USA 1994;91:6369.
56. [56] Rolland PH. Friggi A. Barlaiter A et al. Hyperhomocysteinemia-induced vascular damage in the mini-pig. Circulation 1995;91:1161.
57. [57] Zioncheck TF. Powell LM, Rice GC, Eaton DL, Lawn RM. Interaction of recombinant apolipoprotein(a) and lipoprotein(a) with macrophages. J Clin Invest 1991;87:767.
58. [58] Nachman RL, Gavish D, Azrolan N. Clarkson TB. Lipoprotein(a) in diet-induced atherosclerosis in nonhuman primates. Arterioscler Thromb 1991:11:32.
59. [59] Lawn RM, Wade DP, Hammer RE, Chiesa G, Verstuyft JG, Rubin EM. Atherogenesis in transgenic mice expressing human apolipoprotein(a). Nature 1992;360:670.
60. [60] Hajjar KA, Gavish D, Breslow JL, Nachman RL. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature 1989;339:301.
61. [61] Harpel PC, Gordon BR, Parker TS. Plasmin catalyzes binding of lipoprotein(a) to immobilized fibrinogen and fibrin. Proc Natl Acad Sci USA 1989:86:3847.
62. [62] Loscalzo J, Weinfeld M, Fless GM, Scanu AM. Lipoprotein(a). fibrin binding, and plasminogen activation. Arterioscler Thromb 1990;10:240.
63. [63] Williams JK, Bellinger DA, Nichols TC, Griggs TR, Bumol TF. Fouts RL. Clarkson TB. Occlusive arterial thrombosis in cynomolgus monkeys with varying plasma concentrations of lipoprotein(a). Arterioscler Thromb 1993;13:548.
64. [64] Moliterno DJ, Lange RA, Meidell RS et al. Relation of plasma lipoprotein(a) to infarct artery patency in survivors of myocardial infarction. Circulation 1993;88:935.
65. [65] Sorensen KE, Celermajer DS, Georgakopoulos D, Hatcher D, Betteridge DJ, Deanfield JE. Impairment of endothelium-dependent dilation is an early event in children with familial hypercholesterolemia and is related to lipoprotein(a) level. J Clin Invest 1994;93:50.
66. [66] Galle J, Bengen J, Schollmeyer P, Wanner C. Impairment of endothelium-dependent dilation of rabbit renal arteries by oxidized lipoprotein(a). Circulation 1995; 92:1582.
67. [67] Cook NS, Ubben D. Fibrinogen as a major risk factor in cardiovascular disease. Trends Pharmacol Sci 1990;11:444.
68. [68] Rainer C. Kawanaski DT, Chandraratna N et al. Changes in blood rheology in patients with stable angina pectoris as a result of coronary artery disease. Circulation 1987;76:15.
69. [69] Ernst E. Fibrinogen - an independent cardiovascular risk factor. J Intern Med 1990;227:365.
70. [70] Mansoor MA, Ueland PM, Aarsland A, Svardal AM. Redox status and protein binding of plasma homocysteine and other aminothiols in patients with homocystinuria. Metabolism 1993:42:1481.
71. [71] Guttormsen AB, Svarstad E. Ueland PM, Refsum H. Elimination of homocysteine from plasma in subjects with endstage renal failure. Irish J Med Sci 1995;164:8 (abstract).
72. [72] Selhub J, Jacques PF, Wilson PWF, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. J Am Med Assoc 1993;270:2693.
73. [73] van Guldener C, Janssen MJFM, Surachno J. Short term effect of kidney transplantation on plasma homocysteine in dialysis patients. Irish J Med Sci 1995;164:22 (abstract).
74. [74] Vantenetrghem Y, Roels L, Lerut T et al. Thromboembolic complications and haemostatic changes in cyclosporin-treated cadaveric kidney allograft recipients. Lancet 1985;1:999.
75. [75] Bergstrom J. Nutrition and mortality in hemodialysis. J Am Soc Nephrol 1995;6:1329.
76. [76] Bostom AG, Shemin D, Lapane KL et al. Folate status is the major determinant of fasting total plasma homocysteine in maintenance dialysis patients. Atherosclerosis 1996;123:193-202.
77. [77] Bostom AG, Shemin D, Lapane KL et al. High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int 1996;49:147-152.
78. [78] Bostom AG, Shemin D, Yoburn D, Fisher DH, Nadeau MR, Selhub J. Lack of effect of oral N-acetylcysteine on the acute dialysis-related lowering of total plasma homocysteine in hemodialysis patients. Atherosclerosis 1996; 120:241.
79. [79] Nakahama H, Nakanishi T, Uyama O et al. Niceritrol reduces plasma lipoprotein(a) levels in patients undergoing hemodialysis. Renal Failure 1993;15:189.
80. [80] Bosch T, Samtleben W, Thiery J, Gurland HJ, Seidel D. Reverse flux filtration: a new mode of therapy improving the efficacy of heparin-induced extracorporeal LDL precipitation in hyperlipidemic hemodialysis patients. Int J Art Organ 1993;16:75.